|Event Date/Time: May 22, 2012||End Date/Time: May 24, 2012|
Versatility of monoclonal antibodies and their advantages over conventional drugs, such as their specificity, indicate there is immense scope for research and therapeutic applications. However, with dozens of products currently in various phases of testing, top pharmaceutical and biotechnological companies fight to produce more advanced and effective mAbs. Vigorous competition is bound to be strengthened by expiring patents and consequent entry of biosimilars to the market.
Although monoclonal antibodies offer highly promising potential, they also involve complexity and costliness of production. Moreover, the pressure to reduce spending in current economic climate and safety concerns suggest there are numerous issues to be resolved and overcome.
This visiongain conference is designed to highlight the pathways for growth and address the challenges faced by the industry, while at the same time act as a networking platform for leading researchers and developers. In addition to learning about the latest clinical advancements and breakthroughs, you will have an opportunity to:
- Identify key advances in antibody technology: nanobodies, conjugates, scFvs, and BiTEs
- Discover new therapeutic applications in oncology, autoimmune disorders and ophthalmology
- Gain insight into future for biosimilar mAbs and how they might affect market share
- Investigate the application of phage display libraries and screening techniques to identify new target antigens.
- Review optimised platform approaches to the downstream processing of monoclonal antibodies
- Learn about current clinical and preclinical antibody developments
- Hear about breakthroughs in the monoclonal IgG purification techniques
- Examine how patent expiry will affect access to the antibody engineering